Social media

Pediatric trials face unique complexity but selecting a fit for purpose HRQoL measure doesn’t have to. The FDA’s PFDD Guidance emphasizes that historical use is not justification. Sponsors must demonstrate why an instrum...

Pediatric trials face unique complexity but selecting a fit for purpose HRQoL measure doesn’t have to. The FDA’s PFDD Guidance emphasizes that historical use is not justification. Sponsors must demonstrate why an instrum...

Join us on 6 May at OCT Europe in Barcelona. At 12:00pm in Stream C, Ankita Minhas will present “The global biotech sector: A CRO perspective”. Discover how rising scientific and operational complexity, AI‑driven innovat...

Join us on 6 May at OCT Europe in Barcelona. At 12:00pm in Stream C, Ankita Minhas will present “The global biotech sector: A CRO perspective”. Discover how rising scientific and operational complexity, AI‑driven innovat...

ICON Biotech will participate in #CTOWC26, the 13th Annual Clinical Trials in Oncology West Coast, taking place on 28–29 April 2026 in Burlingame, California. The event brings together oncology and clinical research pr...

ICON Biotech will participate in #CTOWC26, the 13th Annual Clinical Trials in Oncology West Coast, taking place on 28–29 April 2026 in Burlingame, California. The event brings together oncology and clinical research pr...

We’re honoured to be recognised for the second consecutive year at the Asia‑Pacific Biopharma Excellence Awards 2026, winning Best Clinical Trial Supplier: Site Innovation. This award reflects the dedication of our APAC...

We’re honoured to receive the Best Clinical Trial Supplier Award: Site Innovation at the Asia‑Pacific Biopharma Excellence Awards 2026 — our second consecutive win. This recognition reflects the commitment of our APAC t...

For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique advantages. Discover how the expected timeframe, type of data needed and study population can play ...

For long-term vaccine follow-up, traditional onsite studies and newer strategies, such as tokenisation, each have unique advantages. Discover how the expected timeframe, type of data needed and study population can play ...

Operationalising NMA in R The paper provides a clear overview of how netmeta and multinma support high quality analyses. – Netmeta enables contrast based, frequentist NMA with automated network construction and heteroge...

Operationalising NMA in R The paper provides a clear overview of how netmeta and multinma support high quality analyses. – Netmeta enables contrast based, frequentist NMA with automated network construction and heteroge...